| Literature DB >> 32120839 |
Ashok Agarwal1, Manesh Kumar Panner Selvam1, Saradha Baskaran1.
Abstract
Human sperm proteomics research has gained increasing attention lately, which provides complete information about the functional state of the spermatozoa. Changes in the sperm proteome are evident in several male infertility associated conditions. Global proteomic tools, such as liquid chromatography tandem mass spectrometry and matrix-assisted laser desorption/ionization time-of-flight, are used to profile the sperm proteins to identify the molecular pathways that are defective in infertile men. This review discusses the use of proteomic techniques to analyze the spermatozoa proteome. It also highlights the general steps involved in global proteomic approaches including bioinformatic analysis of the sperm proteomic data. Also, we have presented the findings of major proteomic studies and possible biomarkers in the diagnosis and therapeutics of male infertility. Extensive research on sperm proteome will help in understanding the role of fertility associated sperm proteins. Validation of the sperm proteins as biomarkers in different male infertility conditions may aid the physician in better clinical management.Entities:
Keywords: bioinformatics; male infertility; molecular pathways; proteomics; sperm
Mesh:
Substances:
Year: 2020 PMID: 32120839 PMCID: PMC7084638 DOI: 10.3390/ijms21051621
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Workflow involving the processing of semen samples for sperm proteomics.
Key differentially expressed proteins (DEPs) identified by sperm proteomic profiling in various clinical conditions associated with male infertility.
| Clinical Condition | Clinical Scenario | Exclusion/Filtering Criteria | Subjects Enrolled | Samples Used for Proteomics | Method | DEPs | Reference(s) |
|---|---|---|---|---|---|---|---|
| Varicocele | Oligozoospermic patients with varicocele | Systemic illnesses, cryptorchidism, orchitis, epididymitis, urethritis, testicular atrophy, or sexually transmitted diseases, including human immunodeficiency virus. Azoospermia and a sperm concentration <10 million sperm/mL. | 20 | 20 | 2D PAGE MALDI-TOF/TOF-MS | HSPA5, ATP5D, SOD1, ACPP, CLU, PARK7, KLK3, PIP, SEMG2, SEMG2pre | [ |
| Unilateral varicocele | Systemic illnesses, cryptorchidism, orchitis, epididymitis, urethritis, testicular atrophy, or sexually transmitted diseases, including human immunodeficiency virus, Endtz-positive. Azoospermia and a sperm concentration <10 million sperm/mL. | 33 | Pooled sample ( | 1D PAGE LC-MS/MS | CABYR, AKAP, APOPA1, SEMG1, ACR, SPA17, RSPH1, RSPH9 DNAH17, DLD, GSTM3, TGM4, NPC23, ODF2GPR64, PSMA8, HIST1H2BA, PARK7 | [ | |
| Unilateral and bilateral varicocele patients | Endtz-positive. Azoospermia and a sperm concentration <10 million sperm/mL. | Unilateral = 33, bilateral = 17 | Pooled sample ( | 1D PAGE LC-MS/MS | GSTM3, SPANXB1, PARK7, PSMA8, DLD, SEMG1, SEMG2 | [ | |
| Bilateral varicocele | Azoospermia and a sperm concentration <10 million sperm/mL. Smoker and abnormal body mass index | 17 | Pooled sample ( | 1D PAGE LC-MS/MS | ODF2, TEKT3, TCP11, TGM4, CLGN, TOM22, APOA1 | [ | |
| Varicocele | Azoospermia and a sperm concentration <10 million sperm/mL. | 50 | Pooled sample ( | 1D PAGE LC-MS/MS | PKAR1A, AK7, CCT6B, HSPA2, ODF2 | [ | |
| Varicocele | Endtz-positive and sperm concentration less than <10 million sperm/mL. Female factor infertility | 50 | Pooled sample ( | LC-MS/MS | LETM1, EFHC, MIC60, PGAM5, ISOC2, TOM22, NDFSU1, UQCRC2, COX5B, ATPase1A4, HSPA2, SPA17, APOA1 | [ | |
| Testicular cancer | Testicular cancer | NA | 16 | 16 | 1D PAGE LC-MS/MS | PSA, PAcP, ZAG, SEMG 1 and 2, AKAP4, DNAH17 | [ |
| Non-seminoma testicular cancer | NA | 15 | Pooled sample ( | 1D PAGE LC-MS/MS | NDUFS1, UQCRC2, ATP1A4, ANXA2, ATP1A2, ACR | [ | |
| Normozoospermic and asthenozoosperic testicular cancer | NA | Normozoospermic testicular cancer = 20, | Pooled sample ( | 1D PAGE LC-MS/MS | CCT3, ATP5A1, UQCRC2, ATP1A4, MMP9 | [ | |
| asthenozoosperic testicular cancer = 20 | Pooled sample ( | ||||||
| Normozoospermic and asthenozoosperic testicular cancer | NA | Normozoospermic testicular cancer = 20, | Pooled sample ( | 1D PAGE LC-MS/MS | NDUFS1, CD63 | [ | |
| asthenozoosperic testicular cancer = 20 | Pooled sample ( | ||||||
| Testicular cancer seminoma | NA | 15 | Pooled sample ( | 1D PAGE LC-MS/MS | HSPA2, ATP1A4, UQCRC2, ACE | [ | |
| Asthenozoospermia | Rapid motility (grade a) of 0–3% and progressive motility (grade a+b) of 5–20% | NA | 8 | 8 | 2-DE MALDI-TOF MS | IDH-α, ODF, SEMG1, ARHGDIB, GOT1, PGAM2, TPI1, CA2, GS10, MSS1 | [ |
| Progressive motility <25% (grade a) or motile sperm <50% (grades a + b) | NA | 20 | 20 | 2D PAGE MS | ACTB, ANXA5, COX6B, H2A, PIP, PIPpre, S100A9, CLUpre, DLDpre, FHpre, HSPA2, IMPA1, MPST/ECH1pre, PSMB3, SEMG1pre, TEX12 | [ | |
| Rapid linear progression <25% (Grade a) | Sexually transmitted diseases including human immunodeficiency virus (HIV), | 17 | Pooled sample ( | 2D PAGE MALDI MS/MS | TPIS, PSMA3, GKP2, HSPA2, OXCT1, TUBB2C, TEKT1 | [ | |
| Progressive motility <10% | History of long term medication, varicocele and leukocytospermia. Hyperviscous and necrozoospermic samples, viability <70%. | 4 | Nano UPLC–MSE tandem mass spectrometry | GRP78, GAPDHS, HSP70-2, TUBA4A, TUBA3C, TUBA8, ODF1, AKAP3, AKAP4, ROPN1B, SPANXB, CLU, PIP, ATP5B, ALDOA, ARGDIA | [ | ||
| Rapid progressive and slow progressive motility ≤30% | History of depression, diabetes, cancer, hypertension, hyperthyroidism, or sexually transmitted diseases. Exposed to environmental stress, including radiation or chemicals, smokers, and with abnormal body mass index. | 35 | 35 | 2-DE MALDI-TOF/TOF MS | UBB2B, ODF2, AKAP4, KRT1, CLU, COX6B, GAPDS, PHGPx, HSPA2, HSPA9, VDAC2, GSTMu3, ASRGL1, SPANXB | [ | |
| Sperm motility <40% | Endtz-positive. | 10 | 10 | UPLC-MS | PLXNB2, POTEKP, NIN, PHF3, DYNLL1, PROCA1, FASCIN-3; LRRC37B, PLC | [ | |
| Sperm motility <40% | Oligozoospermia, teratozoospermia or leukocytospermia | 4 | 4 | 2-DE MALDI-TOF MS | LFT, ATP5B, DJ-1, PARK7, ODF, TEKT1, AKAP4, ELSPBP1, PDHB, NDUS1, SUCLA2, SDHA | [ | |
| progressive sperm motility ≤32% | HIV positive samples and sexually transmitted diseases. Samples contaminated with blood | 70 | Pooled sample ( | 2D-DIGE MALDI -TOF-MS | TEX40, ATP6V0A2, SERPINB9, PSA | [ | |
| Globozoospermia | Round-headed acrosomeless sperm | NA | 1 | 1 | 2D DIGE MALDI-TOF/TOF MS/MS | SAMP1, ODF2, SPANXa/d, TUBA2, TPI1, PIP | [ |
NA: not available, PAGE: polyacrylamide gel electrophoresis, 1D: 1-dimensional, 2D: 2-dimensional, MALDI: matrix-assisted laser desorption/ionization, TOF: time-of-flight, LC-MS/MS: liquid chromatography-tandem mass spectrometry, UPLC: ultra-performance liquid chromatography.
Figure 2Interaction between the differentially expressed proteins and transcriptional factors in varicocele patients with mitochondrial dysfunction. TOMM22: mitochondrial import receptor subunit TOM22 homolog, COX5B: cytochrome c oxidase subunit 5B, mitochondrial, NDUFS1: NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial, IMMT: NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial, UQCRC2: cytochrome b-c1 complex subunit 2, mitochondrial, PGAM5: serine/threonine-protein phosphatase PGAM5, mitochondrial, TAL1: T-cell acute lymphocytic leukemia protein 1, ACAT1: acetyl-CoA acetyltransferase, mitochondrial, ECHS1: enoyl-CoA hydratase, mitochondrial, ECH1: delta(3,5)-delta(2,4)-dienoyl-CoA isomerase, mitochondrial, LETM1: mitochondrial proton/calcium exchanger protein, IDH3B: isocitrate dehydrogenase [NAD] subunit beta, mitochondrial, c-Src: proto-oncogene tyrosine-protein kinase Src, PRKAR1A: cAMP-dependent protein kinase type I-alpha regulatory subunit, PRKACA: cAMP-dependent protein kinase catalytic subunit alpha, CISY: citrate synthase, mitochondrial, ACO2: aconitate hydratase, mitochondrial, IDH3A: isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial, HADHA: trifunctional enzyme subunit alpha, mitochondrial, ISOC2: isochorismatase domain-containing protein 2, PKC: protein kinase C, NRF2: nuclear factor erythroid 2 (NFE2)-related factor 2, GCR: glucocorticoid receptor, PPAR-β (Δ): peroxisome proliferator-activated receptor beta or delta, YY1: Yin Yang 1, VDR: vitamin D receptor, ATF: activating transcription factor, CREB: cAMP response element binding, OCT-3/4: octamer-binding transcription factor 3/4, AP-1: activator protein 1, SP1: specificity protein 1, ESR1: estrogen receptor 1, ERR1: steroid hormone receptor ERR1, NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells.
DEPs involved in the functional pathways implicated in male infertility.
| Molecular Pathways | DEPs | Reference |
|---|---|---|
| Oxidative stress | HIST1H2BA, MDH2, TGM4, GPX4, GLUL, HSP90B1, HSPA5, ACE, HSPA2, RPS27A, MAP3K3 and APP, PRDX1, AKAP4 | [ |
| Energy and metabolism and Mitochondrial dysfunction | PKAR1A, AK7, CCT6B, HSPA2, ODF2, DLD, ATP5D, NDUFS1, UQCRC2, COX5B, PDH, PHGPx, VDAC, COX6B, AKAP4 | [ |
| Cytoskeleton integrity | ACTB, KRT1, ODF2, TEK1, TEK4, TEK5, TUBB2B, ACTB | [ |
| Protein folding and degradation | HSPA2, CLU, PSMB4, PSMB5, PSMB6, PSMA3 | [ |
| Spermatogenesis and sperm function | Importin, Exportin, HSP 70, AKAPs, HSPA2, | [ |
| Sperm DNA damage | CRISPLD2, CRISPLD2, RARRES1 | [ |